liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Nilsson, Lennart
Alternative names
Publications (10 of 54) Show all publications
Nilsson, L., Blennow, M., Storsaeter, J. & Lepp, T. (2015). Att förebygga kikhosta hos spädbarn: Systematisk litteraturöversikt. Östersund: Folkhälsomyndigheten
Open this publication in new window or tab >>Att förebygga kikhosta hos spädbarn: Systematisk litteraturöversikt
2015 (Swedish)Report (Other academic)
Abstract [sv]

Allmän barnvaccination mot kikhosta återinfördes i Sverige 1996 och sedan dess har antalet rapporterade fall av kikhosta minskat dramatiskt. Sjukdomen förekommer dock fortfarande bland ovaccinerade spädbarn och bland ungdomar och vuxna. Den högsta sjukdomsincidensen i Sverige ses bland spädbarn under sex månaders ålder. Kikhosta är en allvarlig och livshotande sjukdom för spädbarn och hårdast drabbas de allra yngsta som inte har fått sin första vaccindos vid tre månaders ålder. Drygt 70 procent av dem som insjuknar behöver sjukhusvård.

Flera länder har under de senaste åren rapporterat en ökning av kikhostefall i befolkningen och dödsfall på grund av kikhosta hos spädbarn. För att minska sjukdomsbördan hos spädbarnen har rekommendationer i dessa länder innefattat vaccination av vuxna runt det nyfödda barnet (kokongvaccination), vaccination av modern under sista trimestern av graviditeten och vaccination av hälso- och sjukvårdspersonal. Dessutom har man i vissa länder rekommenderat vaccination av vuxna vart tionde år.

Folkhälsomyndigheten har gjort en systematisk litteraturöversikt med syfte att finna evidens enligt GRADE-metodiken för preventiva strategier som minskar förekomsten av kikhosta hos barn yngre än sex månader. De preventiva strategier som har utvärderats är a) striktare följsamhet till tidpunkten för eller tidigareläggning av första vaccindosen, b) neonatal vaccination, c) kokongvaccination, d) vaccination av gravida, e) vaccination vid 4–7 års ålder, f) vaccination vid 13–19 års ålder, och g) postexpositionsprofylax med antibiotika.

Litteraturöversikten visar någon grad av evidens för att alla de utvärderade strategierna bidrar till att skydda spädbarn mot kikhosta, förutom tonårsvaccination. Det finns två vårdinsatser som redan stöds av befintliga föreskrifter och rekommendationer men som bör följas mer strikt.

  • Tidpunkten för första vaccindosen har betydelse för skydd mot kikhosta hos spädbarn. Uträkningar från bland annat det svenska uppföljningsprogrammet talar för en väsentlig minskning av kikhosta hos barn under sex månaders ålder om första vaccindosen ges strikt vid angiven tid enligt vaccinationsschemat eller inom två veckor före den tidpunkten.
  • Det är viktigt att vara uppmärksam på hosta i närfamiljen under barnets första levnadsmånader. Frikostig provtagning, snabb diagnostik och behandling kan förhindra dödsfall i kikhosta hos spädbarn. Tidigt insatt postexpositionsprofylax med antibiotika till spädbarn ger ett gott skydd mot klinisk kikhosta.

Dessutom finns två strategier som ytterligare kan minska förekomsten av kikhosta hos spädbarn under 6 månader:

  • Kokongvaccination
  • Vaccination av gravida.

Kokongvaccination har i några länder visat effekt vid hög anslutning och kostnadsfri vaccination. Vaccination mot kikhosta under graviditet rekommenderas i flera länder. I England har vaccination av gravida erbjudits i cirka tre års tid i vaccinationsprogram och visat god effekt bland spädbarn till vaccinerade mödrar. Uppföljning av programmet och utvärdering av långtidseffekterna pågår och resultaten publiceras allteftersom.

Place, publisher, year, edition, pages
Östersund: Folkhälsomyndigheten, 2015. p. 59
Keywords
Kikhosta, Vaccination
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-124389 (URN)9789176034620 (ISBN)9789176034583 (ISBN)
Available from: 2016-01-28 Created: 2016-01-28 Last updated: 2016-02-01Bibliographically approved
Carlsson, R. M., von Segebaden, K., Bergstrom, J., Kling, A. M. & Nilsson, L. J. (2015). Surveillance of infant pertussis in Sweden 1998-2012; severity of disease in relation to the national vaccination programme. Eurosurveillance, 20(6), Article ID 21032.
Open this publication in new window or tab >>Surveillance of infant pertussis in Sweden 1998-2012; severity of disease in relation to the national vaccination programme
Show others...
2015 (English)In: Eurosurveillance, ISSN 1025-496X, E-ISSN 1560-7917, Vol. 20, no 6, article id 21032Article in journal (Refereed) Published
Abstract [en]

In Sweden, pertussis was excluded from the national vaccination programme in 1979 until acellular vaccination was introduced in a highly endemic setting in 1996. The general incidence dropped 10-fold within a decade, less in infants. Infant pertussis reached 40–45 cases per 100,000 in 2008 to 2012; few of these cases were older than five months. We present an observational 15-year study on the severity of infant pertussis based on 1,443 laboratory-confirmed cases prospectively identified from 1998 to 2012 in the national mandatory reporting system and followed up by telephone contact. Analyses were made in relation to age at onset of symptoms and vaccination history. Pertussis decreased in non-vaccinated infants (2003 to 2012, p < 0.001), indicating herd immunity, both in those too young to be vaccinated and those older than three months. The hospitalisation rates also decreased (last five-year period vs the previous five-year periods, p <0.001), but 70% of all cases in under three month-old infants and 99% of cases with apnoea due to pertussis were admitted to hospital in 1998 to 2012. Median duration of hospitalisation was seven days for unvaccinated vs four days for vaccinated infants aged 3–5 months. Nine unvaccinated infants died during the study period.

Place, publisher, year, edition, pages
EUR CENTRE DIS PREVENTION and CONTROL, 2015
National Category
Other Social Sciences not elsewhere specified Infectious Medicine
Identifiers
urn:nbn:se:liu:diva-114976 (URN)000349381100002 ()
Note

Funding Agencies|National Institute of Allergy and Infectious Diseases [N01-AI-15125]; European Commission [QLK2-CT-2001-01819]; Eupertstrain; GlaxoSmithKline Vaccines, Wavre, Belgium; Sanofi Pasteur, Lyon, France; Sanofi Pasteur MSD, Lyon, France

Available from: 2015-03-10 Created: 2015-03-06 Last updated: 2018-12-13
Abelius, M. S., Janefjord, C., Ernerudh, J., Berg, G., Matthiesen, L., Duchén, K., . . . Jenmalm, M. (2015). The Placental Immune Milieu is Characterized by a Th2- and Anti-Inflammatory Transcription Profile, Regardless of Maternal Allergy, and Associates with Neonatal Immunity. American Journal of Reproductive Immunology, 73(5), 445-459
Open this publication in new window or tab >>The Placental Immune Milieu is Characterized by a Th2- and Anti-Inflammatory Transcription Profile, Regardless of Maternal Allergy, and Associates with Neonatal Immunity
Show others...
2015 (English)In: American Journal of Reproductive Immunology, ISSN 1046-7408, E-ISSN 1600-0897, Vol. 73, no 5, p. 445-459Article in journal (Refereed) Published
Abstract [en]

PROBLEM: How maternal allergy affects the systemic and local immunological environment during pregnancy and the immune development of the offspring is unclear.

METHOD OF STUDY: Expression of 40 genes was quantified by PCR arrays in placenta, peripheral blood mononuclear cells (PBMC), and cord blood mononuclear cells (CBMC) from 7 allergic and 12 non-allergic women and their offspring.

RESULTS: Placental gene expression was dominated by a Th2-/anti-inflammatory profile, irrespectively of maternal allergy, as compared to gene expression in PBMC. p35 expression in placenta correlated with fetal Tbx21 (ρ = -0.88, P < 0.001) and IL-5 expression in PBMC with fetal galectin1 (ρ = 0.91, P < 0.001). Increased expression of Th2-associated CCL22 in CBMC preceded allergy development.

CONCLUSIONS: Gene expression locally and systemically during pregnancy was partly associated with the offspring's gene expression, possibly indicating that the immunological milieu is important for fetal immune development. Maternal allergy was not associated with an enhanced Th2 immunity in placenta or PBMC, while a marked prenatal Th2 skewing, shown as increased CCL22 mRNA expression, might contribute to postnatal allergy development.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2015
National Category
Clinical Medicine Cell and Molecular Biology Immunology in the medical area
Identifiers
urn:nbn:se:liu:diva-114069 (URN)10.1111/aji.12350 (DOI)000352810200007 ()25491384 (PubMedID)
Available from: 2015-02-06 Created: 2015-02-06 Last updated: 2018-01-11
Carlsson, R. M., Gustafsson, L., Hallander, H. O., Ljungman, M., Olin, P., Gothefors, L., . . . Netterlid, E. (2015). Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years. Vaccine, 33(31), 3717-3725
Open this publication in new window or tab >>Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years
Show others...
2015 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 33, no 31, p. 3717-3725Article in journal (Refereed) Published
Abstract [en]

Prior study children from a DTaP efficacy trial were recruited at ages 5 and 15 years to randomized booster trials addressing immunogenicity and reactogenicity; 475 preschool children received mixed or separate injections of a reduced antigen vaccine (Tdap5, Sanofi Pasteur MSD) and an inactivated polio vaccine, and 230 adolescents received the same or another booster vaccine (Tdap1, SSI, Denmark). Pre-vaccination antibody concentrations against pertussis antigens were significantly higher at 15 than 5 years of age, probably due to natural boosting between the studies. Tdap5 induced comparable anti-PT concentrations at both ages, but antibody responses were significantly higher to filamentous haemagglutinin, pertactin and fimbriae 2/3 in adolescents. As expected, a higher amount of PT (Tdap1, 20 mu g) induced a stronger anti-PT response than a lower amount (Tdap5, 2.5 mu g). The frequency of adverse events was low and there were no serious adverse reactions. All local reactions had an early onset and a short duration. A large swelling or redness of more than half of the upper arm circumference was reported in 8/475 5-year-olds and in 6/230 15-year-olds. Children vaccinated with Tdap5 reported more moderate pain in adolescence than at preschool age, whereas itching was only reported in preschool children. Sweden introduced DTaP vaccines in 1996 after a 17-year hiatus with no general pertussis vaccination and pertussis was still endemic at the time of the studies. The frequency of adverse events was nevertheless low in both preschool children and adolescents and antibody responses were adequate. These studies document immunogenicity and reactogenicity in a trial cohort consecutively vaccinated with acellular pertussis vaccines from infancy to adolescence. (C) 2015 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
Elsevier, 2015
Keywords
Pertussis; Diphtheria; Tetanus; Vaccine; Acellular; Booster; Preschool; Adolescent; Immunization; Immunogenicity; Adverse effect; Reactogenicity
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-120448 (URN)10.1016/j.vaccine.2015.05.079 (DOI)000358096000018 ()26057135 (PubMedID)
Note

Funding Agencies|Aventis Pasteur Limited, Toronto, Canada; Aventis Pasteur MSD A/S, Copenhagen, Denmark; Sanofi Pasteur MSD Sweden; Statens Serum Institut (SSI) Denmark

Available from: 2015-08-12 Created: 2015-08-11 Last updated: 2017-12-04
Abelius, M. S., Janefjord, C., Ernerudh, J., Berg, G., Matthiesen, L., Duchén, K., . . . Jenmalm, M. (2014). Gene expression in placenta, peripheral and cord blood mononuclear cells from allergic and non-allergic women.
Open this publication in new window or tab >>Gene expression in placenta, peripheral and cord blood mononuclear cells from allergic and non-allergic women
Show others...
2014 (English)Manuscript (preprint) (Other academic)
Abstract [en]

Background: The influence of maternal allergy on the development of immune responses and allergy in the offspring is not understood.

Objective: To investigate (i) if maternal allergy influences the gene expression locally in placenta, systemically in peripheral blood mononuclear cells (PBMC) and fetally in cord blood mononuclear cells (CBMC), (ii) if the gene expression in the placenta and PBMC influences the gene expression in CBMC and (iii) how the gene expression at birth relates to allergy development during  childhood.

Methods: A real-time PCR array was used to quantify forty immune regulatory genes in placenta, PBMC (gestational week 39) and in CBMC from 7 allergic and 12 non-allergic women and their offspring. Furthermore, quantitative real-time PCR was used to measure mRNA expression of Tbx21, GATA-3, Foxp3, RORC and CCL22 in CBMC, selected based on present PCR array results and previous protein findings in cord blood, in 13 children who developed and 11 children who did not develop allergy during childhood.

Results: The gene expression profile in the placenta revealed a T-helper (Th) 2-/anti-inflammatory environment as compared with gene expression systemically, in PBMC. Maternal allergy was associated with increased expression of p35 in PBMC and CBMC and p40 in placenta. Placental p35 expression correlated with fetal Tbx21 expression (Rho=-0.88, p<0.001) and maternal IL-5 expression in PBMC with fetal Galectin-1 (Rho=0.91, p<0.001) expression. Allergy development in the children was preceded by high mRNA expression of the Th2-associated chemokine CCL22 at birth.

Conclusion and clinical relevance: Gene expression locally and systemically during pregnancy influenced the offspring’s gene expression at birth, indicating an interplay between maternal and fetal immunity. Children developing allergy during childhood had an increased expression of the Th2-associated chemokine CCL22 at birth, indicating a Th2 skewing before disease onset. Maternal allergy was not associated with a Th2-dominance in placenta, PBMC or CBMC.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-106219 (URN)
Available from: 2014-04-29 Created: 2014-04-29 Last updated: 2015-03-25Bibliographically approved
Vogt, H., Bråbäck, L., Kling, A.-M., Grünewald, M. & Nilsson, L. (2014). Pertussis Immunization in Infancy and Adolescent Asthma Medication. Pediatrics, 134(4), 721-728
Open this publication in new window or tab >>Pertussis Immunization in Infancy and Adolescent Asthma Medication
Show others...
2014 (English)In: Pediatrics, ISSN 0031-4005, E-ISSN 1098-4275, Vol. 134, no 4, p. 721-728Article in journal (Refereed) Published
Abstract [en]

Context: Lack of infections might contribute to increased risk of asthma among children according to the ‘hygiene hypothesis’. Childhood immunization may play a causal role in the development of asthma.

Objective: To determine whether pertussis immunization in infancy is associated with asthma medication in adolescence.

Design, Settings and Participants: After 14 years of no general pertussis vaccination, almost 80,000 children were immunized for pertussis during a 12-month period in a vaccination trial. They were compared with almost 100,000 non-vaccinated children born during a 6-month period before and after the vaccination trial in a Swedish national cohort study. Information concerning dispensed prescribed asthma medication for each individual in the cohort during 2008–2010 was obtained from the National Prescription database. Multivariable regression models were used to calculate the effect size of vaccination on dispensed asthma medication (Odds ratios and 95% confidence intervals), both in an intent-to-treat model as well as per protocol. The large study size also enabled us to detect very small effects.

Main Outcome Measure: Dispensed prescribed asthma medication at the age of 15 years occurring after pertussis immunization in infancy.

Results: No statistically significant effect of vaccination was found, regardless of vaccination schedule or vaccine type. The prevalence rates of any dispensed anti-inflammatory medication or any asthma medication at 15 years of age were 4.6% and 7.0%, respectively. The crude odds ratios (OR) for any asthma medication and anti-inflammatory treatment in pertussis-vaccinated children after intent-to-treat analysis were 0.97 (95% CI 0.93 – 1.00) and 0.94 (0.90 – 0.98),respectively. Corresponding adjusted ORs were 0.99 (0.95 – 1.03) and 0.97 (0.92 – 1.01),respectively. Similar ORs were found after per-protocol analysis.

Conclusion: Pertussis immunization in infancy does not increase the risk of asthma medication in adolescents. Our study presents evidence that pertussis immunization in early childhood can be considered safe with respect to long-term development of asthma.

Place, publisher, year, edition, pages
APP Journals & Periodicals, 2014
National Category
Pediatrics
Identifiers
urn:nbn:se:liu:diva-85157 (URN)10.1542/peds.2014-0723 (DOI)000343140500055 ()
Note

On the day of the defence date the status of this article was Manuscript and the title was Does pertussis in infancy increase the risk of asthma medication in adolescents?.

Available from: 2012-11-07 Created: 2012-11-07 Last updated: 2017-12-07Bibliographically approved
Jahnmatz, M., Ljungman, M., Netterlid, E., Jenmalm, M., Nilsson, L. & Thorstensson, R. (2014). Pertussis-Specific Memory B-Cell and Humoral IgG Responses in Adolescents after a Fifth Consecutive Dose of Acellular Pertussis Vaccine. Clinical and Vaccine Immunology, 21(9), 1301-1308
Open this publication in new window or tab >>Pertussis-Specific Memory B-Cell and Humoral IgG Responses in Adolescents after a Fifth Consecutive Dose of Acellular Pertussis Vaccine
Show others...
2014 (English)In: Clinical and Vaccine Immunology, ISSN 1556-6811, E-ISSN 1556-679X, Vol. 21, no 9, p. 1301-1308Article in journal (Refereed) Published
Abstract [en]

In order to impede the increase in pertussis incidence in the adolescent group, a school-leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden in 2016. Preceding this introduction, an open-label, randomized, multicenter, clinical trial without a control group and with blinded analysis was performed, investigating both safety and immunogenicity. Reported here are the memory B-cell and serological responses detected in a smaller cohort (n = 34) of the 230 subjects recruited to the study. All subjects had received primary vaccination consisting of three doses of diphtheria-tetanus-5-component pertussis (DTaP5) vaccine, at 3, 5, and 12 months of age, and a tetanus-low-dose diphtheria-5-component pertussis (Tdap5) vaccine booster at 5.5 years. In this study, the subjects were randomly assigned and received either a Tdap1 or Tdap5 booster. Of the 230 participants, 34 subjects had samples available for evaluation of IgG-producing memory B-cell responses. Both vaccine groups had significant increases in pertussis toxin-specific serum IgG levels, but only the 1-component group showed significant increases in pertussis toxin-specific memory B cells. The 5-component group had significant increases in filamentous hemagglutinin- and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected. In conclusion, this study shows that a 5th consecutive dose of an acellular pertussis vaccine induces B-cell responses in vaccinated adolescents.

Place, publisher, year, edition, pages
American Society for Microbiology, 2014
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-111261 (URN)10.1128/CVI.00280-14 (DOI)000341624800015 ()25008903 (PubMedID)
Note

Funding Agencies|Statens Serum Institute; Sanofi Pasteur MSD (Sweden)

Available from: 2014-10-15 Created: 2014-10-14 Last updated: 2017-10-31
Abelius, M. S., Lempinen, E., Lindblad, K., Ernerudh, J., Berg, G., Matthiesen, L., . . . Jenmalm, M. (2014). Th2-like chemokine levels are increased in allergic children and influenced by maternal immunity during pregnancy. Pediatric Allergy and Immunology, 25(4), 387-393
Open this publication in new window or tab >>Th2-like chemokine levels are increased in allergic children and influenced by maternal immunity during pregnancy
Show others...
2014 (English)In: Pediatric Allergy and Immunology, ISSN 0905-6157, E-ISSN 1399-3038, Vol. 25, no 4, p. 387-393Article in journal (Refereed) Published
Abstract [en]

Background: The influence of the intra-uterine environment on the immunity and allergy development in the offspring is unclear. We aimed to investigate (i) whether the pregnancy magnifies the Th2 immunity in allergic and non-allergic women, (ii) whether the maternal chemokine levels during pregnancy influenced the offspring’s chemokine levels during childhood and (iii) the relationship between circulating Th1/Th2-associated chemokines and allergy in mothers and children.

Methods: The Th1-associated chemokines CXCL9, CXCL10, CXCL11, and the Th2- associated chemokines CCL17, CCL18 and CCL22 were quantified by Luminex and ELISA in 20 women with and 36 women without allergic symptoms at gestational week (gw) 10–12, 15–16, 25, 35, 39 and 2 and 12 months post-partum and in their children at birth, 6, 12, 24 months and 6 yr of age. Total IgE levels were measured using ImmunoCAP Technology.

Results: The levels of the Th2-like chemokines were not magnified by pregnancy. Instead decreased levels were shown during pregnancy (irrespectively of maternal allergy status) as compared to post-partum. In the whole group, the Th1-like chemokine levels were higher at gw 39 than during the first and second trimester and post-partum. Maternal CXCL11, CCL18 and CCL22 levels during and after pregnancy correlated with the corresponding chemokines in the offspring during childhood. Increased CCL22 and decreased CXCL10 levels in the children were associated with sensitisation and increased CCL17 levels with allergic symptoms during childhood. Maternal chemokine levels were not associated with maternal allergic disease.

Conclusions: Allergic symptoms and sensitisation were associated with decreased Th1-and increased Th2-associated chemokine levels during childhood, indicating a Th2 shift in the allergic children, possibly influenced by the maternal immunity during pregnancy.

Place, publisher, year, edition, pages
John Wiley & Sons, 2014
Keywords
Allergy; CCL17; CCL22; chemokines; pregnancy; Th2
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-106218 (URN)10.1111/pai.12235 (DOI)000338037100013 ()
Available from: 2014-04-29 Created: 2014-04-29 Last updated: 2017-12-05Bibliographically approved
Vogt, H., Bråbäck, L., Zetterström, O., Zara, K., Fälth-Magnusson, K. & Nilsson, L. (2013). Asthma heredity, cord blood IgE and asthma-related symptoms and medication in adulthood: a long-term follow-up in a Swedish birth cohort. PLoS ONE, 8(6), e66777.
Open this publication in new window or tab >>Asthma heredity, cord blood IgE and asthma-related symptoms and medication in adulthood: a long-term follow-up in a Swedish birth cohort
Show others...
2013 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 8, no 6, p. e66777.-Article in journal (Refereed) Published
Abstract [en]

Cord blood IgE has previously been studied as a possible predictor of asthma and allergic diseases. Results from different studies have been contradictory, and most have focused on high-risk infants and early infancy. Few studies have followed their study population into adulthood. This study assessed whether cord blood IgE levels and a family history of asthma were associated with, and could predict, asthma medication and allergy-related respiratory symptoms in adults.

A follow-up was carried out in a Swedish birth cohort comprising 1701 consecutively born children. In all, 1661 individuals could be linked to the Swedish Prescribed Drug Register and the Medical Birth Register, and 1227 responded to a postal questionnaire. Cord blood IgE and family history of asthma were correlated with reported respiratory symptoms and dispensed asthma medication at 32–34 years.

Elevated cord blood IgE was associated with a two- to threefold increased risk of pollen-induced respiratory symptoms and dispensed anti-inflammatory asthma medication. Similarly, a family history of asthma was associated with an increased risk of pollen-induced respiratory symptoms and anti-inflammatory medication. However, only 8% of the individuals with elevated cord blood IgE or a family history of asthma in infancy could be linked to current dispensation of anti-inflammatory asthma medication at follow-up.

Elevated cord blood IgE and a positive family history of asthma were associated with reported respiratory symptoms and dispensed asthma medication in adulthood, but their predictive power was poor in this long-time follow-up.

Keywords
birth cohort, cord blood, family history, prediction, prescription
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:liu:diva-85156 (URN)10.1371/journal.pone.0066777 (DOI)000320846500104 ()
Note

The status of this article was on the day of the defence date Manuscript.

Available from: 2012-11-07 Created: 2012-11-07 Last updated: 2017-12-07Bibliographically approved
Nilsson, L., Von Segebaden, K., Blennow, M., Linde, A. & Uhnoo, I. (2013). [Whooping cough is a risk to infants. The disease is circulating among adolescents and adults].. Läkartidningen, 110(37), 1599-1602
Open this publication in new window or tab >>[Whooping cough is a risk to infants. The disease is circulating among adolescents and adults].
Show others...
2013 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 110, no 37, p. 1599-1602Article in journal (Refereed) Published
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-114070 (URN)24163932 (PubMedID)
Available from: 2015-02-06 Created: 2015-02-06 Last updated: 2017-12-04
Organisations

Search in DiVA

Show all publications